- Home
- WHF vs TLSA Comparison
WHF vs TLSA Comparison
Compare WHF & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | TLSA |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | United States | United Kingdom |
| Employees | 3 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 145.1M |
| IPO Year | 2012 | 2017 |
Fundamental Metrics
Financial Performance| Metric | WHF | TLSA |
|---|---|---|
| Price | $7.12 | $1.02 |
| Analyst Decision | Sell | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | 55.3K | ★ 997.9K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 13.67% | N/A |
| EPS Growth | ★ 31.91 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $16.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.07 | $0.87 |
| 52 Week High | $8.97 | $2.35 |
Technical Indicators
Market Signals| Indicator | WHF | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 59.60 | 41.03 |
| Support Level | $7.08 | $0.90 |
| Resistance Level | $7.21 | $1.20 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 59.27 | 15.59 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.